Prognostic significance of phosphoglycerate dehydrogenase in breast cancer

Knockdown of Kinase family 15 inhibits cancer cell proliferation in vitro and its Clinical relevance in Triple-Negative Breast Cancer

(2019) Jiayu Sheng et al.   CURRENT MOLECULAR MEDICINE

Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma

(2019) Qing Li et al.   CANCER LETTERS

Targeted Therapies for Triple-Negative Breast Cancer

(2019) Tomas G. Lyons   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Timing and Delays in Breast Cancer Evaluation and Treatment

(2018) Richard J. Bleicher   ANNALS OF SURGICAL ONCOLOGY

PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer

(2018) Zhiwang Song et al.   GENE

Creating prognostic systems for cancer patients: A demonstration using breast cancer

(2018) Mathew T. Hueman et al.   Cancer Medicine

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics

(2017) A J Lucanus et al.   ONCOGENE

PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis

(2017) Boxi Zhang et al.   Cell Reports

The importance of serine metabolism in cancer

(2016) Katherine R. Mattaini et al.   JOURNAL OF CELL BIOLOGY

Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer

(2016) Xiao-qin Jia et al.   Translational Oncology

Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer

(2016) Judith E. Unterlass et al.   Oncotarget

The chicken chorioallantoic membrane model in biology, medicine and bioengineering

(2014) Patrycja Nowak-Sliwinska et al.   ANGIOGENESIS

Phosphoglycerate Dehydrogenase: Potential Therapeutic Target and Putative Metabolic Oncogene

(2014) Cheryl K. Zogg   Journal of Oncology

Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer

(2013) N. Patani et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Chick Chorioallantoic Membrane (CAM) Assay as an In Vivo Model to Study the Effect of Newly Identified Molecules on Ovarian Cancer Invasion and Metastasis

(2012) Noor A. Lokman et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting glucose metabolism for cancer therapy: Figure 1.

(2012) Robert B. Hamanaka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

(2011) Richard Possemato et al.   NATURE

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis

(2011) Jason W Locasale et al.   NATURE GENETICS

PHGDH amplification and altered glucose metabolism in human melanoma

(2011) Edouard Mullarky et al.   Pigment Cell & Melanoma Research

GOBO: Gene Expression-Based Outcome for Breast Cancer Online

(2011) Markus Ringnér et al.   PLoS One

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE